C. Manegold

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

Martin Reck, Joachim von Pawel, Petr Zatloukal et al. · Annals of Oncology · 2010 · 640 citations · Full text

First-line Therapy, Oncology, Overall Survival +8

Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency

Louis‐Daniel Brun, Lock Hock Ngu, Wee Teik Keng et al. · Neurology · 2010 · 219 citations

Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975

Fabio Efficace, Andrew Bottomley, Egbert F. Smit et al. · Annals of Oncology · 2006 · 182 citations

Quality Of Life, Life Assessment, Self-reported Health-related Quality +10

Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704

C. Manegold, Joachim von Pawel, Petr Zatloukal et al. · Journal of Clinical Oncology · 2007 · 167 citations

Neuro-oncology, Lba7514 Background, Chemotherapy-naïve Patients +15

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma

J M W van Haarst, Paul Baas, C. Manegold et al. · British Journal of Cancer · 2002 · 158 citations · Full text